Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015 (2015), Article ID 591580, 6 pages
http://dx.doi.org/10.1155/2015/591580
Review Article

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children

Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Commenda 9, 20122 Milan, Italy

Received 30 September 2014; Revised 6 January 2015; Accepted 10 January 2015

Academic Editor: Antoni Torres

Copyright © 2015 Susanna Esposito and Nicola Principi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Conklin, J. D. Loo, J. Kirk et al., “Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children,” Pediatric Infectious Disease Journal, vol. 33, supplement 2, pp. S109–S118, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. Centers for Disease Control and Prevention (CDC), “Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United States, 1998–2003,” Morbidity and Mortality Weekly Report, vol. 54, pp. 893–897, 2005. View at Google Scholar
  3. N. Principi, E. Baggi, and S. Esposito, “Prevention of acute otitis media using currently available vaccines,” Future Microbiology, vol. 7, no. 4, pp. 457–465, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. M. R. Griffin, Y. Zhu, M. R. Moore, C. G. Whitney, and C. G. Grijalva, “U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination,” The New England Journal of Medicine, vol. 369, no. 2, pp. 155–163, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. D. J. Isaacman, E. D. McIntosh, and R. R. Reinert, “Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines,” International Journal of Infectious Diseases, vol. 14, no. 3, pp. e197–e209, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. S. I. Pelton, H. Huot, J. A. Finkelstein et al., “Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine,” Pediatric Infectious Disease Journal, vol. 26, no. 6, pp. 468–472, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. A. F. Messina, K. Katz-Gaynor, T. Barton et al., “Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005,” Pediatric Infectious Disease Journal, vol. 26, no. 6, pp. 461–467, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. Food and Drug Administration, Vaccines: approved products. Prevnar 13 (pneumococcal 13-valent conjugate vaccine), 2014, http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201667.htm.
  9. European Medicines Agency, European Published Assessment Reports, Prevenar 13, 2014, http://www.ema.europa.eu/ema/index.jsp?searchType=name&startLetter=P&taxonomyPath=&keyword=Enter+keywords&alreadyLoaded=true&curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&mid=WC0b01ac058001d125&searchGenericType=generics&treeNumber=&searchTab=&pageNo=2.
  10. L. Jódar, J. Butler, G. Carlone et al., “Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants,” Vaccine, vol. 21, no. 23, pp. 3265–3272, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. S. A. Plotkin, “Correlates of protection induced by vaccination,” Clinical and Vaccine Immunology, vol. 17, no. 7, pp. 1055–1065, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. R. Moore, “Update on effectiveness and impact of PCV13 use among U.S. children,” http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2014-02/02-Pneumo-Moore.pdf.
  13. R. Singleton, J. Wenger, J. A. Klejka et al., “The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in alaska native children: results of a clinical trial,” Pediatric Infectious Disease Journal, vol. 32, no. 3, pp. 257–263, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. W. H. B. Demczuk, I. Martin, A. Griffith et al., “Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012,” Canadian Journal of Microbiology, vol. 59, no. 12, pp. 778–788, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. N. J. Andrews, P. A. Waight, P. Burbidge et al., “Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study,” The Lancet Infectious Diseases, vol. 14, no. 9, pp. 839–846, 2014. View at Publisher · View at Google Scholar
  16. Z. B. Harboe, T. Dalby, D. M. Weinberger et al., “Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality,” Clinical Infectious Diseases, vol. 59, no. 8, pp. 1066–1073, 2014. View at Publisher · View at Google Scholar
  17. S. Ben-Shimol, D. Greenberg, N. Givon-Lavi et al., “Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance,” Vaccine, vol. 32, no. 27, pp. 3452–3459, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Levy, E. Varon, C. Picard et al., “Trends of pneumococcal meningitis in children after introduction of the 13-valent pneumococcal conjugate vaccine in France,” The Pediatric Infectious Disease Journal, vol. 33, no. 12, pp. 1216–1221, 2014. View at Publisher · View at Google Scholar
  19. G. E. Lee, S. A. Lorch, S. Sheffler-Collins, M. P. Kronman, and S. S. Shah, “National hospitalization trends for pediatric pneumonia and associated complications,” Pediatrics, vol. 126, no. 2, pp. 204–213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. C. G. Grijalva, J. P. Nuorti, P. G. Arbogast, S. W. Martin, K. M. Edwards, and M. R. Griffin, “Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis,” The Lancet, vol. 369, no. 9568, pp. 1179–1186, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Esposito and N. Principi, “Pneumococcal vaccines and the prevention of community-acquired pneumonia,” Pulmonary Pharmacology and Therapeutics, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. M. C. Pírez, G. Algorta, F. Chamorro et al., “Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and haemophilus influenzae type b conjugate vaccine in a pediatric referral hospital in Uruguay,” Pediatric Infectious Disease Journal, vol. 33, pp. 753–759, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Becker-Dreps, E. Amaya, L. Liu et al., “Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua,” The Pediatric Infectious Disease Journal, vol. 33, no. 6, pp. 637–642, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Angoulvant, C. Levy, E. Grimprel et al., “Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children,” Clinical Infectious Diseases, vol. 58, no. 7, pp. 918–924, 2014. View at Publisher · View at Google Scholar
  25. B. Fireman, S. B. Black, H. R. Shinefield, J. Lee, E. Lewis, and P. Ray, “Impact of the pneumococcal conjugate vaccine on otitis media,” Pediatric Infectious Disease Journal, vol. 22, no. 1, pp. 10–16, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Eskola, T. Kilpi, A. Palmu et al., “Efficacy of a pneumococcal conjugate vaccine against acute otitis media,” The New England Journal of Medicine, vol. 344, no. 6, pp. 403–409, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Hoberman, J. L. Paradise, N. Shaikh et al., “Pneumococcal resistance and serotype 19A in Pittsburgh-area children with acute otitis media before and after introduction of 7-valent pneumococcal polysaccharide vaccine,” Clinical Pediatrics, vol. 50, no. 2, pp. 114–120, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. H. J. Adam, J. A. Karlowsky, K. A. Nichol et al., “Baseline epidemiology of Streptococcus pneumoniae serotypes in Canada prior to the introduction of the 13-valent pneumococcal vaccine,” Microbial Drug Resistance, vol. 18, no. 2, pp. 176–182, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Cohen, C. Levy, E. Bingen, M. Koskas, I. Nave, and E. Varon, “Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media,” Pediatric Infectious Disease Journal, vol. 31, no. 3, pp. 297–301, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Ben-Shimol, N. Givon-Lavi, E. Leibovitz, S. Raiz, D. Greenberg, and R. Dagan, “Near elimination of otitis media caused by the PCV13 serotypes in Southern Israel shortly after sequential introduction of PCV7/PCV13,” Clinical Infectious Diseases, 2014. View at Publisher · View at Google Scholar
  31. A. S. Zhao, S. Boyle, A. Butrymowicz, R. D. Engle, J. M. Roberts, and J. Mouzakes, “Impact of 13-valent pneumococcal conjugate vaccine on otitis media bacteriology,” International Journal of Pediatric Otorhinolaryngology, vol. 78, no. 3, pp. 499–503, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Simell, K. Auranen, H. Käyhty, D. Goldblatt, R. Dagan, and K. L. O'Brien, “The fundamental link between pneumococcal carriage and disease,” Expert Review of Vaccines, vol. 11, no. 7, pp. 841–855, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. A. M. Loughlin, K. Hsu, A. L. Silverio, C. D. Marchant, and S. I. Pelton, “Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts' children,” The Pediatric Infectious Disease Journal, vol. 33, pp. 504–510, 2014. View at Google Scholar
  34. A. J. van Hoek, C. L. Sheppard, N. J. Andrews et al., “Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England,” Vaccine, vol. 32, pp. 4349–4355, 2014. View at Publisher · View at Google Scholar · View at Scopus